Rigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company’s chairman and chief executive officer, is scheduled to present a company overview at two investor conferences in New York City in February. Details of the presentations are as follows:
16(th) Annual BIO CEO & Investor Conference
Monday, February 10 at 2:00 p.m. ET
RBC Capital Markets Global Healthcare Conference
Tuesday, February 25 at 11:00 a.m. ET
Both presentations will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel’s pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP and a Phase 2 clinical trial for IgA nephropathy in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an AMPK activator entering Phase 1 in early 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.
Contact: Ryan Maynard
SOURCE Rigel Pharmaceuticals, Inc.